A study from the Division of Molecular Medicine and Genetics, Department of Internal Medicine, The Life Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, USA shows that “Snail1-dependent p53 repression regulates expansion and activity of tumour-initiating cells in breast cancer” This study was published in the 17 October 2016 issue of the journal “Nature Cell Biology” [the number 1 journal in Cell Biology with an I.F of 18.699] by Prof. Stephen J. Weiss, Ting Ne, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Breast Cancer: DEAR1/TRIM62 increases the level of tumor suppressor p53, inhibits the proliferation of tumor-initiating cells in breast cancer, suppresses the progression of metastatic breast cancer, and supports tumor relapse-free survival in breast cancer patients
Given that: (1) cancer causes the highest economic loss compared to all the known causes of death worldwide; (2) in 2008, breast cancer has caused more than 400000 deaths; (3) in 2011, 17 lakhs new cases of breast cancer diagnosed; (4) breast cancer is the most common invasive cancer in women; and (5) in 2008, breast cancer has caused economic loss of 88 billion US dollars worldwide, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; (ii) a side-effect-free natural product-based drug; and (iii) a way to effectively treat and stall metastatic progression and relapse of breast cancer.
Breast cancer is the most common women cancer. Interestingly, compared to other women cancers, breast cancer not only metastasizes frequently but also relapses. However, the mechanistic basis of which remains largely unclear.
What we infer from what they say:
Stephen’s research team has recently shown that increased expression of the EMT (Epithelial-to-mesenchymal transition) regulator Snail1 promotes: (1) degradation of tumor suppressor p53 in breast cancer cells; and (2) expansion and activity of tumor-initiating cells that aid in relapse of breast cancer, suggesting that inhibition of metastatic promoter Snail1 expression in breast cancer cells will not only inhibit the progression of metastatic breast cancer but also prevent relapse.
What we say:
This study suggests a small molecule-based therapy for metastatic breast cancer. DEAR1/TRIM62, by decreasing the expression of its target gene, it may increase the expression of tumor suppressor p53. Thereby, it may inhibit metastasis and relapse of breast cancer.
Thus, pharmacological formulations encompassing “DEAR1/TRIM62 activators“ may be used to treat metastatic breast cancer.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, Molecular therapy for Breast Cancer: TRIM protein DEAR1/TRIM62 increases the level of tumor suppressor p53, inhibits the proliferation of tumor-initiating cells in breast cancer, suppresses the progression of metastatic breast cancer, and supports tumor relapse-free survival in breast cancer patients, 25/October/2015, 7.20 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Undisclosed information: How TRIM protein DEAR1/TRIM62 increases the expression of tumor suppressor p53 and inhibits the proliferation of tumor-initiating cells in metastatic breast cancers?
Results guaranteed if not refunded